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Abstract
Summary The present study shows no adverse effects of the
anti-diabetic drug metformin on bone mass and fracture
healing in rodents but demonstrates that metformin is not
osteogenic in vivo, as previously proposed.
Introduction In view of the increased incidence of fractures
in patients with type 2 diabetes mellitus (T2DM), we inves-
tigated the effects of metformin, a widely used T2DM
therapy, on bone mass and fracture healing in vivo using
two different rodent models and modes of metformin
administration.
Methods We first subjected 12-week-old female C57BL/6
mice to ovariectomy (OVX). Four weeks after OVX, mice
received either saline or metformin administered by gavage
(100 mg/kg/daily). After 4 weeks of treatment, bone micro-
architecture and cellular activity were determined in tibia by
micro-CT and bone histomorphometry. In another experi-
ment, female Wistar rats aged 3 months were given only
water or metformin for 8 weeks via the drinking water
(2 mg/ml). After 4 weeks of treatment, a mid-diaphyseal
osteotomy was performed in the left femur. Rats were
sacrificed 4 weeks after osteotomy and bone architecture
analysed by micro-CT in the right tibia while fracture
healing and callus volume were determined in the left femur
by X-ray analysis and micro-CT, respectively.
Results In both models, our results show no significant
differences in cortical and trabecular bone architecture in
metformin-treated rodents compared to saline. Metformin
had no effect on bone resorption but reduced bone formation
rate in trabecular bone. Mean X-ray scores assessed on
control and metformin fractures showed no significant dif-
ferences of healing between the groups. Fracture callus
volume and mineral content after 4 weeks were similar in
both groups.
Conclusions Our results indicate that metformin has no
effect on bone mass in vivo or fracture healing in rodents.
Keywords Bone architecture . Fracture healing .
Histomorphometry . Metformin . Micro-CT
Introduction
Metformin is widely prescribed as a first-line therapy for
patients with type 2 diabetes mellitus (T2DM) as an anti-
hyperglycaemic agent which acts primarily by suppressing
glucose production by the liver [1]. In contrast to
thiazolidinediones (TZD), another T2DM therapy which
has adverse effects on the skeleton [2, 3], several studies
have documented that metformin is osteogenic in vitro. It
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was reported that metformin can induce MC3T3-E1 osteo-
blastic cells differentiation and bone matrix synthesis via
adenosine 5′-monophosphate-activated protein kinase
(AMPK) activation and subsequent induction of endothelial
nitric oxide synthase (eNOS) and bone morphogenetic
protein-2 (BMP-2) expression [4, 5]. Metformin was also
found to regulate Small Heterodimer Partner (SHP) in
MC3T3-E1 cells, an orphan nuclear receptor which stimu-
lates osteoblastic bone formation by interacting with the
transcription factor Runx2 [6]. Similarly, metformin in-
creased osteoblast proliferation, alkaline phosphatase activ-
ity and the number of mineralised nodules formed in rat
primary osteoblasts, possibly via stimulation of Runx2 and
IGF-1 production [7, 8]. The action of metformin on bone
marrow mesenchymal cell progenitors (BMPCs) has also
been investigated and metformin caused an osteogenic ef-
fect, suggesting a possible action of metformin in promoting
a shift of BMPCs towards osteoblastic differentiation [9]. In
contrast, two in vitro studies have shown no effect of met-
formin on the osteogenic differentiation of bone marrow-
derived mesenchymal stem cells (MSCs) [10] and matrix
mineralisation of both MC3T3-E1 cells and primary osteo-
blasts [11]. A high concentration of metformin (2 mM) even
clearly inhibited osteoblast differentiation [11].
Less work has investigated the effect of metformin on
bone in vivo, and the data are more supportive also of an
osteogenic effect of metformin. It was reported that 2 months
of treatment with metformin prevents the bone loss induced
by ovariectomy in rats [12, 13], suggesting protective effects
of metformin against bone loss. In agreement with these
studies, a 2-week treatment with metformin in rats was
shown to increase trabecular volume, osteocyte density
and osteoblast number in femoral metaphysis [14]. Further-
more, when administered together with the TZD
rosiglitazone, metformin prevented the anti-osteogenic ef-
fects of rosiglitazone on bone [14]. A very recent study
performed in insulin-resistant mice also showed that met-
formin given for 6 weeks protects femoral bone architecture
compared to rosiglitazone, although metformin had no ef-
fect on lumbar spine [15]. However, few clinical studies
have shown beneficial effects of metformin on bone health.
Metformin was shown to reduce the association between
diabetes and fractures in human patients [16]. More stud-
ies have confirmed that rosiglitazone therapy alone or
combined rosiglitazone and metformin therapies were as-
sociated with a higher risk of fractures compared to met-
formin as a monotherapy [17–20]. Interestingly, markers
of bone formation were decreased in the metformin group
compared to the rosiglitazone one in T2DM patients from
the ADOPT study [21].
The aim of our study was to confirm the osteogenic effect
of metformin in vivo on bone architecture in basal condi-
tions (control rats) and in osteopenic bone, using a model of
bone loss induced by ovariectomy (ovariectomised mice) to
mimic the case of post-menopausal women. For each model,
we used different modes of metformin administration that
have both been utilised in previous rodent studies; while
ovariectomised mice had metformin administered orally by
gavage, control rats received metformin in the drinking
water. We also wanted to explore the hypothesis that met-
formin promotes fracture healing in a rat model of mid-
diaphyseal, transverse osteotomy in the femur, stabilised
via a precision miniature external fixator. Surprisingly, we
show in this study that 1- to 2-month treatment with met-
formin, regardless of the administration route, has no sig-
nificant effect on rodent bone architecture and fracture
healing in vivo, and that metformin significantly reduces
bone formation rate in osteopenic trabecular bone.
Materials and methods
Animals and experimental procedures
Experimental procedures used 3-month-old female Wistar
rats (Charles River Laboratories, Inc., Margate, UK) and 3-
month-old female mice that were in a mixed C57BL/6-
129Sv genetic background. These mice were bred in our
animal facilities and housed in groups of five in polypro-
pylene cages. Wistar rats were allowed to acclimatise for
1 week after transport before the start of experiments and
were housed individually. Both rats and mice were subjected
to a 12 h light/dark cycle with room temperature maintained
at 21 °C. For mice, metformin (Sigma-Aldrich Company
Ltd, Dorset, UK) was given by gavage 100 mg/kg/daily. For
rats, metformin was given in the drinking water at a con-
centration of 2 mg/ml for 8 weeks. On average, water
consumption in rats is 10–12 ml per 100 g body weight
daily and metformin did not affect the drinking volume.
These metformin doses were previously shown to give
similar plasma concentrations in rodents than those found
therapeutically in humans. The drinking water, along with
food, was available ad libitum. The water bottles were
replenished twice a week. All animal experimentation pro-
cedures were in compliance with Home Office approval and
were performed under the threshold of the UK Animals
(Scientific Procedures) Act 1986.
Effect of metformin on bone mass in ovariectomised mice
The first experiment was designed to investigate whether
metformin could protect against the bone loss induced by
ovariectomy. Eighteen female C57BL/6-129Sv mice aged
3 months were all ovariectomised, as previously performed
by us [22, 23]. Four weeks after ovariectomy, mice were
divided randomly into two groups, one (n=9) receiving
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saline while the other one (n=9) receiving metformin
(100 mg/kg) daily by gavage for 4 weeks. At days 6 and 3
prior to euthanasia, mice were intraperitoneally injected
with calcein (Sigma-Aldrich) and alizarin red complexone
(Sigma-Aldrich), respectively, to label bone-forming sur-
faces in trabecular bone. At the end of the experiment, mice
were sacrificed, the serum collected for measurement of
metformin concentration, the tibia dissected for micro-CT
analysis of cortical and trabecular bone parameters and bone
histomorphometry while the femora were used for protein
isolation and RT–PCR analysis. Since we did not have a
SHAM group, the success of ovariectomy was evaluated by
uterine atrophy observations during dissection.
Effect of metformin on bone mass and fracture healing in rats
The second experiment was designed to investigate the effect
of metformin on basal bone mass. For this study, we used the
right contra-lateral tibia of non-ovariectomised female rats
which underwent a fracture in the left femur. Twenty female
Wistar rats of approximately 200 g were divided randomly
into two groups, one (n=10) having access to drinking water
alone while the other (n=10) receiving metformin in the
drinking water (2 mg/ml) for 8 weeks. Four weeks after the
beginning of treatment, all the rats (n=20) underwent a mid-
diaphyseal transverse osteotomy in the left femur as de-
scribed previously [24]. Surgery was performed under gen-
eral anaesthesia (ketamine 75 mg/kg and xylazine 10 mg/kg)
and appropriate gaseous anaesthesia using aseptic tech-
niques. The external fixator system used in this protocol
comprises two metal blocks of titanium alloy linked to two
cylindrical stainless steel bars. Briefly, the fixator was ap-
plied to the craniolateral aspect of the femur using four
threaded M1.2 stainless steel pins. Consistent positioning
of the fixator pins was ensured using a drill locator template.
After pin placement, a transverse osteotomy was created
midway between the proximal and distal pins using an os-
cillating diamond bone saw, with saline irrigation through-
out. The bone fragments were distracted to leave an
osteotomy gap of 0.5 mm that was maintained by locking
the fixator blocks on to the connecting bars. The rats were
administered with 0.1 cc of Vetergesic (Alstoe Ltd, York,
UK) for analgesia and 0.05 cc of cephalosporin (Sandoz Ltd,
Camberley, UK), as a single dose to prevent infection, post-
operatively and were returned to their cages. They were
granted mobility immediately after regaining consciousness.
Radiographs of the operation site were taken at 4 weeks post-
fracture, the time where rats were euthanised under anaes-
thesia via the delivery of CO2 into an inhalation chamber.
Right tibiae were collected for micro-CT analysis of cortical
and trabecular bone parameters while left osteotomised fem-
ora were collected for micro-CT analysis of fracture callus
and histology.
Micro-CT analysis of mouse and rat tibiae
Right tibiae were harvested from 5-month-old OVX female
C57BL/6-129Sv mice, fixed in 10 % neural-buffered for-
malin for 24–72 h and stored in 70 % ethanol at 4 °C. These
tibia were then scanned with high-resolution (5 μm pixel
size) micro-computed tomography (micro-CT, SkyScan
1172; SkyScan, Kontich, Belgium), as previously described
[7]. Right tibiae from the fracture study were dissected from
rats, fixed and stored as above and scanned with a lower
resolution of 14 μm pixel size due to the size of the bones.
The whole tibiae were reconstructed using NRecon v.1.4.4.0
(SkyScan) and bone histomorphometric analyses in two and
three dimensions (2D, 3D) were performed by SkyScan
software (CT-Analyser v.1.5.1.3). For the analysis of trabec-
ular bone, the cortical shell was excluded by operator-drawn
regions of interest and 3D algorithms were used to deter-
mine the relevant parameters which included bone volume
percentage (BV/TV), trabecular thickness, trabecular num-
ber, trabecular spacing, structure model index (SMI), tra-
becular pattern factor and degree of anisotropy. Analysis of
cortical bone was performed using a 0.49-mm-long segment
(or 100 tomograms) at 37 % of the tibias' length from its
proximal end. For analysis of the cortical bone compart-
ment, 2D computation was used and parameters were deter-
mined for each one of the 100 tomograms and then
averaged. They included periosteal perimeter, endosteal pe-
rimeter and cortical thickness.
Assessment of fracture healing
X-ray analysis
Radiographs were taken at the study end point (8 weeks),
prior to euthanasia. Both dorsal and ventral X-rays were
performed to assess the extent of in situ healing and bridging
of the fracture space. Fracture healing was scored from two
dimensions, anterior–posterior and lateral–medial X-rays.
The X-rays were scored using a three-point system, 1—no
callus, 2—some callus formation and 3—significant callus,
on all four cortices. The lowest score is thus 4, signifying no
callus formation on all four cortices, and a highest of 12,
significant callus growth in all four regions.
Micro-CT analysis of fracture healing
Left femora (fractured side) were scanned at 14 μm reso-
lution using micro-CT (SkyScan 1172). A length of ap-
proximately 15 mm of the callus with the fracture in the
centre was scanned. Histomorphometric analysis of fracture
callus in 2D and 3D was performed by SkyScan software
(v. 1.11.8.0). A ‘shrink-wrap’ algorithm was used to define
the tissue perimeter as the volume of interest (VOI).
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Binarisation of the reconstructed datasets was by two
methods that applied different thresholds since the fracture
callus 4 weeks after fracture is heterogeneous and may
contain low or highly mineralised woven bone; to automat-
ically delineate the low mineralised callus, a specific
threshold was applied that excluded the highly mineralised
callus and cortical bone. After measurement, another
thresholding was applied, which in contrast defined highly
mineralised callus and cortical bone, excluding the very
low mineralised callus. Two relevant parameters were
therefore quantified, cortical and mineralised callus volume
and low mineralised callus volume.
Histology
After micro-CT analysis, fracture calluses were decalcified
in 0.34 M EDTA in PBS for 2 weeks at room temperature,
bisected longitudinally and the lateral half embedded in
paraffin as described previously [25]. Sagittal sections
(5 μM) were cut from the paraffin blocks using a microtome
(HM360; Fisher Scientific UK Ltd, Loughborough, UK).
Sections were stained with haematoxylin and eosin (H&E)
for basic morphology and with Alcian blue and nuclear fast
red for analysis of cartilage and bone.
Histomorphometry analysis of tibia
Tibia were fixed in 10 % neutral-buffered formalin for
24 h, dehydrated and embedded in methyl methacrylate
(MMA) at low temperature to preserve enzymatic activity
[26]. Unstained 8-μm-thick sections were used for fluo-
rescence microscopy to assess mineral apposition rate
(MAR, μm/day). Mineralising surfaces were expressed
as alizarin red-labelled surfaces per bone surfaces
(MS/BS, %) and the bone formation rate was calculated
as MS/BS×MAR (BFR/BS, μm3/μm2/day) [27]. Alterna-
tively, sections were stained for tartrate-resistant acid
phosphatase (TRAP) (Leucognost® SP; Merck, Germany)
and counterstained with Weigert haematoxylin solution.
Histomorphometric parameters were measured on the tra-
becular bone of the metaphysis, on a region of interest
consisting of 2 mm width below the growth plate. Measure-
ments were performed using an image analysis software
(Tablet’measure; Explora Nova, La Rochelle, France).
Histomorphometric parameters were reported in accor-
dance with the ASBMR Committee nomenclature [28].
Protein extraction and western blot analysis
For the isolation of total proteins, right femora from 5-month-
old female C57BL/6-129Sv mice were carefully dissected and
all their surrounding musculature removed leaving the peri-
osteum intact. We also dissected femora from wild-type
C57BL/6 mice that were injected with metformin at
100 mg/kg/daily only for 3 days. The cartilaginous ends of
the bones were separated and the remaining femoral shafts
were flushed with PBS to remove the marrow. The femoral
shafts were then snap-frozen and pulverised under liquid
nitrogen using a mortar and pestle, and then lysed in cold
denaturing lysis buffer (2 % SDS, 2 M urea, 8 % sucrose,
20 mM sodium glycerophosphate, 1 mM sodium fluoride
and 5 mM sodium orthovanadate). Proteins were denatured
by boiling for 10 min and concentrations determined by
BCA protein assay. Twenty micrograms of proteins was
size-fractionated using SDS–PAGE and electrotransferred
onto Protran nitrocellulose membranes (Schliecher and
Schuell, Dassel, Germany). Membranes were blocked for
1 h in 0.2 % (w/v) I-block (Topix, Bedford, MA, USA)
before being incubated with primary antibodies. The blots
were incubated overnight at 4 °C with antibodies against
total AMPKα1/2 (tAMPK α1/2, rabbit), phospho-(Thr-172)-
AMPKα1/2 (pAMPKα1/2, rabbit) (New England Biolabs,
Hitchin, UK) and β-actin (goat) (Dako, Ely, UK), all added at
a 1:1,000 dilution. The following secondary antibodies were
used, goat anti-rabbit (New England Biolabs) against tAMPK
and pAMPK1α1/2 and rabbit anti-goat (Dako) againstβ-actin
antibody, both at 1:2,500 dilution at room temperature for 1 h.
Proteins were visualised using the enhanced chemilumines-
cence detection system (ECL) (GE Healthcare UK Ltd, Little
Chalfont, UK). The intensity of the specific bands was quan-
tified by densitometry using Image J software.
RNA extraction and quantitative real-time PCR
Total RNA was isolated from left whole femora after re-
moval of the bone marrow, as previously described [7].
RNA from three femora in each treatment group was pooled
and two separate extractions were performed. Total RNA
was reverse-transcribed with Superscript II reverse tran-
scriptase. Real-time QPCR was carried out as described
earlier [29] using QuantiTect SYBR green PCR kit and
Opticon 2 LightCycler (MJ Research, Waltham, MA,
USA). Primer sequences were obtained from Qiagen and
are summarised in Table 1. The expression levels for Osterix
and Runx2 were normalised to the reference gene 18s rRNA.
Plasma quantification of metformin
Concentrations of basal metformin level in plasma were
determined using a modified ultra high-pressure liquid
chromatography (UHPLC) assay with UV DAD (diode
array detector) as initially described [30]. Liquid–liquid
extraction of metformin was performed as follows: 200 μl
of plasma sample was buffered by adding 200 μl of 8 M
sodium hydroxide and spiked with 40 μl phenylbiguanide
(internal standard). Then 2.6 ml of a mixture of 50:50
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1-butanol/n-hexane was added, the mixture centrifuged and
200 μl of 1 % acetic acid was added to the upper organic layer.
The mixture was centrifuged, the upper organic layer
discarded and 5 μl of the aqueous layer was then injected
onto a Kinetex® Hilic column (100 × 4.6 mm ID, 2.6 μm)
maintained at 40 °C. Flow rate was set 1 ml/min and com-
pounds were detected at 234 nm on an Agilent DAD (1260
Infinity®). Retention times for phenylbiguanide and metfor-
min were respectively 3.0 and 4.5 min. Lower limit of quan-
tification was 15 ng/ml. Based on quality control samples,
intraday and between-days precision and accuracy were less
than 10 % over the entire range of quantification.
Statistics
The results were presented as mean values ± SD. Statistical
analysis was performed using a two-tailed Mann–Whitney
U test with GraphPad Prism software. P values less than
0.05 were considered to be statistically significant.
Results
Metformin has no effect on in vivo bone loss induced
by ovariectomy in mice
To investigate the effect of metformin on the bone loss
induced by ovariectomy in tibia, we subjected 12-week-
old female C57BL/6-129Sv mice to ovariectomy (OVX)
and metformin treatment by gavage for 4 weeks. To confirm
that metformin treatment administered by gavage was effec-
tive, we assessed metformin concentration in plasma and
showed its detection solely in the plasma of the treatment
group (Fig. 1a). Four weeks of treatment with metformin
induced a trend for total body weight loss in mice, although
this did not reach statistical significance (Fig. 1b). Visceral
and subcutaneous fat weights were not modified by metfor-
min treatment (Fig. 1c).
The analysis of bone micro-architecture determined by
micro-CT in tibia of metformin-treated OVX mice showed
no significant changes in both the trabecular and cortical
compartments compared to control mice (Fig. 2). Metformin
had no effect on trabecular bone volume (BV/TV), trabec-
ular number and thickness compared to saline (Fig. 2a–c).
Other trabecular parameters such as trabecular separation,
bone pattern factor, degree of anisotropy and SMI (not
shown) were also not statistically different between saline-
and metformin-treated mice. Similarly, metformin had no
significant effect on cortical thickness and periosteal and
endosteal perimeters (Fig. 2d–f).
Metformin decreases bone formation parameters
in ovariectomised mice
We examined bone cellular activities in the tibia of
ovariectomised mice using bone histomorphometry. Analysis
of bone formation rate using double fluorescence labelling
showed that metformin decreases the mineralising surfaces
and MAR compared to control mice (MS/BS—metformin,
44.19±15.1 % vs. control, 56.38±7.13 %, P=0.14; MAR—
metformin 1.25±0.14μm/day vs. control, 1.38±0.16μm/day,
P=0.2) and significantly reduces the bone formation rate
(Fig. 3a) (BFR—metformin, 0.543±0.168 μm3/μm2/day vs.
control, 0.778±0.116μm3/μm2/day, P=0.02). The percentage
of TRAP positive surfaces (osteoclast surfaces) was not dif-
ferent in the metformin-treated mice compared to control mice
(metformin, 5.93 ±2.29 %vs. control, 5.01±2.18 %; P=0.31)
(Fig. 3b).
Metformin has no effect on bone mass in vivo in rats
To analyse the effect of metformin on bone mass in vivo, we
submitted 3-month-old female Wistar rats to metformin
treatment during 8 weeks. In this experiment, metformin
was given in the drinking water, a mode of administration
which has been previously shown to be effective in rats at
this concentration [31]. Metformin did not significantly af-
fect rat body weight after 8 weeks of treatment (metformin,
223.4±14.1 g vs. saline, 232.8±16.6 g, P=0.1). Our micro-
CT analysis of tibia from saline- and metformin-treated rats
showed no significant effect of metformin on bone trabecular
(Fig. 4a–c) and cortical parameters (Fig. 4d–f). Metformin
induced a non-significant increase in BV/TV, trabecular
number and trabecular thickness (Fig. 4a–c). Trabecular
separation was decreased by metformin treatment, but it was
not significant (metformin, 0.16±0.01 vs. saline, 0.18±0.01,
P=0.1), as well as SMI (metformin, 0.69±0.32 vs. saline,
1.28±0.15, P=0.2) and trabecular bone pattern factor (met-
formin, −0.27±2.7 vs. saline, 4.34±2.07, P=0.2). Metformin
had no effect on the cortical parameters (Fig. 4d–f).
Table 1 Quantitative real-time RT–PCR primer sequences (5′→3′)
Gene Sequence (forward) Sequence (reverse) Position Length (bp) PrimerBank IDs
Runx2 GACTGTGGTTACCGTCATGGC ACTTGGTTTTTCATAACAGCGGA 474–557 84 225690525b1
Osterix ATGGCGTCCTCTCTGCTTG TGAAAGGTCAGCGTATGGCTT 1–156 156 18485518a1
18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 5231–5381 151 NR_003286.2
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Fig. 1 Effect of metformin treatment on plasma metformin concentra-
tion, body and tissue weights in ovariectomised mice. a Metformin
concentration was quantified by HPLC analysis in plasma of all mice
after 4 weeks of treatment with saline and metformin. b Body weight
difference between start and end of metformin treatment period in
ovariectomised wild-type mice. c Weights of i subcutaneous fat and
ii visceral fat after 4 weeks of treatment with saline and metformin in
































































































Fig. 2 Effect of metformin treatment on trabecular and cortical bone
parameters in tibia of 5-month-old ovariectomised wild-type mice. a, b,
c Three-dimensionally computed BV/TV (a), trabecular number (b) and
trabecular thickness (c) were assessed by micro-CT in the proximal
tibial metaphysis of saline- and metformin-treated mice. d, e, f Two-
dimensionally computed cortical thickness (d), periosteal perimeter (e) and
endosteal perimeter (f) were assessed by micro-CT in the mid-diaphysis of
cortical bone in saline- andmetformin-treatedmice. Bars represent mean ±
SD of n=9 mice/group
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Metformin has no effect on fracture healing after 4 weeks
We evaluated the effect of metformin treatment on fracture
healing in rats 4 weeks after fracture. Radiography showed that
not all fractures were united after 4 weeks. We had to exclude
three rats due to fractures at the pin site and wound dehiscence
decreasing the total number of rats to 17. The final number of
rats for each group was eight in the control group and nine in
the metformin group. To assess the state of fracture healing, X-
ray scoring was carried out on four cortices using radiographic
images. Mean X-ray scores of both control and metformin-
treated groups showed no significant differences between
groups (Fig. 5a). Representative 3D views of callus structure
for both groups are illustrated in Fig. 5c. Large periosteal
calluses are visible at the fracture site in both the control and
metformin-treated groups. Data for fracture callus volumes are
shown in Fig. 5b. Volumes of both low mineralised callus and
highly mineralised callus and cortical bone were similar be-
tween control and metformin groups, suggesting that metfor-
min treatment does not affect fracture callus size or speed of
healing. Figure 5d shows representative images of H&E- and
Alcian blue-stained fracture calluses at 4 weeks in saline and
metformin-treated groups. The original cortical bone and site
of fracture are evident. The callus of both groups contained
cartilage as demonstrated by Alcian blue staining and small
regions of primary trabecular-like bone throughout the callus
area. Metformin did not affect the progression of endochondral
ossification and fracture healing 4 weeks after osteotomy,
confirming the micro-CT data (Fig. 5d).
Metformin does not activate AMPK in bone nor regulate
expression of osteoblast-specific transcription factors
Since AMPK activation has been shown to be important for
osteogenesis [7] and is involved in metformin’s mechanism of
action [32], we studied the involvement of AMPK activation in
its effects on bone. We found that short-term treatment (3 days)
of C57BL/6 wild-type mice with metformin stimulates AMPK
phosphorylation in liver while having no effect on AMPK
phosphorylation in bone (Fig. 6a). Our results also show no
significant increase in AMPK phosphorylation in femora and
fat of ovariectomised C57BL/6-129Sv mice after 4 weeks of
treatment with metformin (Fig. 6b). These results indicate that
AMPK is not activated by short and prolonged metformin
treatment in bone. We did not detect any difference in Osterix
and Runx2 expressions in femora between the saline and met-
formin groups after 4 weeks treatment (Fig.6c), indicating that
metformin does not activate osteoblast-specific gene markers.
Discussion
With the increasing worldwide prevalence of T2DM which
predisposes patients to osteoporosis and increased risk of
fractures [33, 34], there is an increasing need to evaluate the
skeletal actions of anti-diabetic drugs and to examine their
effects on healing of osteoporotic fractures. We show in this
study that the anti-diabetic drug metformin is not ‘bone
unfriendly’ but has no osteogenic action, as previously
reported. In contrast, our data indicate that metformin re-
duces bone formation rate, has no major effect on bone mass
in vivo in rodents and does not promote fracture healing.
We first used ovariectomised mice to examine the skeletal
effect ofmetformin in conditions of low bonemass that aremore
representative of the frequent secondary osteoporosis observed
in T2DM patients. Our results, which show no effect of metfor-
min on bone architecture, contrast with two previous studies
performed in ovariectomised rats [12, 13], demonstrating that
metformin inhibits the trabecular bone loss [12] and the decrease
in bone mineral density [13] induced by OVX. In both studies,
metformin was also administered to OVX rats by gavage at an
identical concentration with the one used in our work. Although
we did not perform a dose–response of metformin in our study,
the concentration of metformin given orally has been extensive-
ly used in previous rodent studies [35, 36]. Our metformin








































Fig. 3 Effect of metformin treatment on bone histomorphometry pa-
rameters measured in tibia of 5-month-old ovariectomised wild-type
mice. a Bone formation rate (BFR) measured on trabecular region of
mouse tibia sections labelled with calcein and alizarin red from saline-
and metformin-treated mice. b Percentage of TRAP-stained surfaces/
bone surfaces in trabecular region of mouse tibia sections from saline-
and metformin-treated mice. Values are mean ± SD of n=6/7 mice/
group, *P=0.02
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detected with a value of approximately 0.3 mg/l. In addition,
metformin induced a small decrease in bodyweight in our study,
a known effect of this anti-diabetic drug which promotes satiety,
reducing the food intake [37]. It is therefore difficult to reconcile
our data with these previous rat studies, all the more since Gao’s
study [12] showed similar trabecular bone mass to ours after
OVX and we previously showed that same-age OVX mice on
this C57BL/6-129Sv background can experience large increases
in trabecular bone volume when treated with intermittent PTH
[23]. The duration of metformin treatment is unlikely to explain
those differences since we treated our mice with metformin for
1 month, but our rats for 2 months, similarly to the previous rat
studies. The effects of metformin on bone may however vary
depending on the rodent species and strain utilised, as previously
demonstrated for the skeletal effect of rosiglitazone [38, 39]. In
our second study, we used non-OVX rats to examine the effect
of metformin on basal bone mass. Rats were used as we wanted
to utilise the non-fractured legs of our model of mid-diaphyseal,
transverse osteotomy in the rat femur. Metformin was given this
time in the drinking water as this mode of administration is less
stressful than gavage for fracture experiments and also widely
used. Similarly, we found no effect of metformin on bone
architecture in contrast to a recent publication by Sedlinsky et
al. [14] showing by histology analysis that metformin increases
trabecular area when administered to non-OVX adult rats for
2 weeks in the drinking water, at similar concentration, but in a
different strain of rats. Although trabecular and cortical bone
architectural parameters were not measured in this study using
micro-CT, osteoblast numbers and resorption surfaces were
quantified on paraffin sections and were both stimulated by
metformin treatment, suggesting that metformin increases bone
remodelling in favour of formation [14]. In our mouse study,
dynamic bone parameters measurements were performed in un-
decalcified sections of tibiae, and we found that osteoclast
surfaces were not affected by metformin treatment. In addition,
we showed that the dynamic measure of bone formation, BFR,
was significantly decreased in trabecular bone by metformin.
This resulted from reduction of both MAR and MS/BS which
reflects decreased osteoblast number and activity, although these
two parameters of bone formation, when independent, were not
decreased significantly with metformin treatment. The demon-
stration that metformin has no resulting effect on trabecular bone
architecture, despite inducing a significant decrease in BFR in
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Fig. 4 Effect of metformin on trabecular and cortical bone parameters
in rat tibia aged 5 months treated with saline and metformin during
8 weeks. a, b, c Three-dimensionally computed BV/TV (a), trabecu-
lar number (b) and trabecular thickness (c) were assessed by micro-
CT in the proximal tibial metaphysis of saline- and metformin-treated
rats. d, e, f Two-dimensionally computed cortical thickness (d), periosteal
perimeter (e) and endosteal perimeter (f) were assessed by micro-CT in
the mid-diaphysis of cortical bone in saline- and metformin-treated rats.
Bars represent mean ± SD of n=9 rats/group
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metformin, possibly affecting osteoblastogenesis. These results
are in agreement with the demonstration that markers of osteo-
blast activitywere reduced for women andmen in themetformin
group compared to the rosiglitazone one in T2DM patients from
the ADOPT study [21]. However, similarly to Wang’s study
[15], our preliminary results did not demonstrate changes in
expression of osteoblast-specific transcription factors measured
by quantitative RT–PCR in metformin-treated bones compared
to control ones. The discrepancies between all these in vivo
studies may therefore also arise from the fact that they measured
diverse bone and cellular parameters.
Studies that have investigated the in vitro effects of
metformin on bone have also shown discrepancies. While
the majority of studies reported osteogenic effects of met-
formin in vitro [4–9, 40], there are reports indicating that
metformin has no osteogenic effect [10] or inhibits osteo-
blast differentiation [11]. Metformin was also shown to
inhibit osteoclast differentiation in vivo and in vitro by
stimulating osteoprotegerin and inhibiting RANKL expres-
sions [13, 41], although Bak et al. [40] showed no effect of
metformin on osteoclast formation. Few clinical studies in
diabetic patients have assessed the effect of metformin as a
monotherapy on fracture risk, and they show overall poor
evidence that it has major anabolic effects on bone. No
direct links between metformin and falls [42] were demon-
strated, and data regarding the association of metformin
with fracture risk are unclear [16, 43, 44]. Borges et al.
[45] have recently shown that 80 weeks of metformin treat-
ment in drug-naïve T2DM patients induces very modest
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Fig. 5 Effect of metformin on bone fracture healing. a X-ray scoring
results for fractured femora in control and metformin-treated rats
4 weeks after fracture. b Analysis of the reconstructions of the fracture
callus using the 3D SkyScan software. The volumes of highly
mineralised callus and bone (i) and low mineralised callus (ii) are not
significantly different in control and metformin-treated groups. Bars
represent mean ± SD of n=8/9 rats/group. c Representative
reconstructed 3D images of rat fracture callus in control and metfor-
min-treated groups. The dark blue colour represents cortical bone and
highly mineralised callus and the bluish green colour trabecular bone
and low mineralised callus. d H&E- and Alcian blue-stained longitu-
dinal sections of fracture callus in control and metformin-treated rats.
At 4 weeks, fractures appeared mostly bridged and the overall fracture
callus size in the two groups was the same. There was also no obvious
visible difference in bone and cartilage composition in control and
metformin-treated groups, as shown by Alcian blue staining. Right
arrow fracture gap, bm bone marrow, cb cortical bone, pc periosteal
callus, mc medullary callus, c cartilage, tb trabecular-like bone
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metformin treatment was recently shown to decrease circu-
lating sclerostin levels in men with T2DM [46], suggesting
that it could improve skeletal fragility in those patients.
More clinical studies have compared the effects of com-
bined TZDs and metformin therapies to TZDs alone and
have more consistently shown that metformin decreases
fracture risk compared to TZDs [17–20].
Metformin is an AMPK agonist [32, 47], and our previ-
ous work has established that AMPK is important for bone
mass in vivo [7, 23]. The contribution of AMPK to the
skeletal action of metformin is unknown. Our results dem-
onstrate that both 3-day and 1-month treatments with met-
formin did not stimulate AMPK phosphorylation in bone in
WTand OVX mice, respectively. The absence of association
between metformin treatment and AMPK activation in bone
in vivo may suggest that metformin’s effect on bone could
be more relevant in the context of diabetes and primarily
indirect by reducing the inflammatory state, the accumula-
tion of advanced glycation end-products (AGEs) and the
formation of reactive oxygen species (ROS).
We show for the first time that metformin, at the dose given,
has no effect on fracture healing in a model of mid-diaphyseal
transverse osteotomy in rats. We evaluated the effect of met-
formin 4 weeks after fracture to examine the endochondral
ossification process, and our data show no effect of metformin
on callus size or on the speed of the healing process. Diabetes
Subcutaneous 






























Fig. 6 Effect of metformin treatment on AMPKα phosphorylation in
bone. a, iWestern blot analysis of pAMPKα1/2, tAMPKα1/2 levels in
bone and liver after 3 days of treatment with metformin (100 mg/kg).
Representative immunoblots are shown, repeated with similar results
twice; a, ii all blots were quantified using image J and the pAMPK to
tAMPK ratio relative to β-actin was determined for each experiment.
Bars represent mean ± SD, n=4 biological samples *P<0.05. b, i
Western blot analysis of pAMPKα1/2, tAMPKα1/2 levels in subcuta-
neous and visceral fat depots and in femur of ovariectomised wild-type
mice treated with metformin (100 mg/kg) for 1 month. Representative
immunoblots are shown, repeated with similar results twice. b, ii Blots
were quantified using image J and the pAMPK to tAMPK ratio relative
to β-actin was determined for each experiment. Bars represent mean ±
SD, n=4 biological samples. c Results show expression of Osterix and
runt related transcription factor 2 (Runx2) normalised to 18s rRNA in
femora of saline and metformin groups after 1 month of treatment. Two
separate RNA extractions were performed for each treatment group,
each time RNA being pooled from three femora
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mellitus has been associated with impaired fracture healing,
mainly due to suppressed osteoblastogenesis caused by low
expression of genes that control osteoblast differentiation
[48–53]. Both intramembranous and endochondral ossification
are impaired and diabetic bone shows delayed bone regenera-
tion [53]. The effects of anti-diabetic drugs on fracture healing
have not been extensively studied. Molinuevo et al. [9] have
found that metformin treatment stimulates bone lesion regen-
eration in a defect model in parietal bone in control and
diabetic rats. Similarly, Sedlinsky et al. [14] have shown, in a
similar minimal lesion defect in rats, that metformin treatment
increases the reossification of this small lesion while
rosiglitazone impaired it. Interestingly, metformin increased
TRAP activity in these parietal bone lesions, a marker of
osteoclast activity. Our data suggest that metformin does not
affect the endochondral ossification process, but we cannot
exclude that metformin could have an effect on the
remodelling of the fracture callus and its mechanical strength.
Our study has several limitations, including the use of a
single dose of metformin and the fact that we did not inves-
tigate the impact of T2DM on the skeletal effect of metformin.
Nevertheless, it strongly indicates that metformin does not
promote bone formation or fracture repair in non-diabetic
rodent models, in contrast to the increased osteogenesis shown
in several in vitro and in vivo studies. This suggests that,
similarly to what was shown for TZDs, the skeletal effects
of metformin are not always observed and could vary
depending on factors such as the strain/sub-strain of rodents,
gender, age, dose and duration of treatment as well as the
hormonal and the inflammatory states.
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